Official Title
Evaluation of Pulmonary Fibrosis After Severe Interstitial Pneumonia Due to COVID-19 (SARS-CoV-2)
Brief Summary

Patients discharged after hospitalization for COVID-19 pneumonia were retrospectivelyselected by radiologically established criteria that at admission presented at chestcomputed tomography (CT) (i) normal lung parenchyma 10%. All At discharge and after 9 months, all subjectsunderwent cardiological evaluation, echocardiogram, pulmonary function tests (PFT) bothatby 3 and by 12 months after discharge. Chest CT was performed by 12 months afterdischarge and chest CT. Specifically, the magnitude of pulmonary involvement betweenbaseline and follow-up was considered the primary endpoint of this study. Secondaryendpoints of the study were results of respiratory function testing, echocardiographicparametersparameters, and persistence of symptoms.

Detailed Description

Not Provided

Completed
Pulmonary Fibrosis
COVID-19

Radiation: Computed tomography

Follow-up computed tomography at 3-6 months and 12 months
Other Name: Pulmonary function test,Echocardiography

Eligibility Criteria

Inclusion Criteria:

- Age ≥ 18

- Hospitalization for severe COVID-19 pneumonia

- Computed tomography during index hospitalization that showed: (i) normale lung
parenchyma < 50% of total lung volume and/or (ii) parenchymal consolidation > 10%

- Cardiological and pneumological visit, echocardiography and pulmonary function test
at 3 and 12 months from hospital discharge

- Computed tomography by 12 months from hospital discharge

Exclusion Criteria:

- Age < 18

- Absence of previously cited test.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Italy
Locations

IRCCS San Raffaele
Milan 3173435, Lombardy 3174618, Italy

Gabriele Fragasso, MD, Principal Investigator
IRCCS San Raffaele

IRCCS San Raffaele
NCT Number
Keywords
Covid-19
Pulmonary fibrosis
ARDS
Computed tomography
pulmonary function test
MeSH Terms
Pulmonary Fibrosis
COVID-19
Respiratory Physiological Phenomena